Canadian Biomarker Integration Network for Depression Study
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This study is a pilot to assess feasibility of the protocol in patients and controls across
six participating sites. The goal is to identify biological markers (biomarkers)that can be
measured at baseline or early in treatment to predict treatment outcome in individual
patients with Major Depressive Disorder (MDD). Biomarkers of interest will be clinical (using
interview and self-report measures), molecular (from blood samples) and neurobiological
(using neuroimaging and EEG).
Phase:
Phase 3
Details
Lead Sponsor:
University Health Network, Toronto
Collaborators:
Centre for Addiction and Mental Health McGill University McMaster University Queen's University University of British Columbia University of Calgary University of Toronto